Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
-

Safety

  • Share Share this page
-

Kepivance (palifermin)

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- May 2009

 

The detailed view includes drug products with safety labeling changes to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, or PATIENT PACKAGE INSERT/MEDICATION GUIDE sections. Deletions or editorial revisions made to these sections are not included in this summary.

 

Summary View

 

PRECAUTIONS

Drug Interactions

  • in vivo drug interaction study results with unfractionated heparins added

Carcinogenesis, Mutagenesis, Impairment of Fertility

  • carcinogenicity results

 

    
-
-
-
-
-